These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 7669372)
1. Delayed diagnosis of cystic fibrosis in children with a rare genotype (delta F508/R117H). Fitzgerald D; Van Asperen P; Henry R; Waters D; Freelander M; Wilson M; Wilcken B; Gaskin K J Paediatr Child Health; 1995 Jun; 31(3):168-71. PubMed ID: 7669372 [TBL] [Abstract][Full Text] [Related]
2. Sweat chloride concentrations in infants homozygous or heterozygous for F508 cystic fibrosis. Farrell PM; Koscik RE Pediatrics; 1996 Apr; 97(4):524-8. PubMed ID: 8632940 [TBL] [Abstract][Full Text] [Related]
3. Screening for cystic fibrosis: the importance of using the correct tools. Shah U; Moatter T J Ayub Med Coll Abbottabad; 2006; 18(1):7-10. PubMed ID: 16773960 [TBL] [Abstract][Full Text] [Related]
4. Pancreatic function and extended mutation analysis in DeltaF508 heterozygous infants with an elevated immunoreactive trypsinogen but normal sweat electrolyte levels. Massie RJ; Wilcken B; Van Asperen P; Dorney S; Gruca M; Wiley V; Gaskin K J Pediatr; 2000 Aug; 137(2):214-20. PubMed ID: 10931414 [TBL] [Abstract][Full Text] [Related]
5. Cystic fibrosis screening in neonates--measurement of immunoreactive trypsin and direct genotype analysis for delta F508 mutation. Larsen J; Campbell S; Faragher EB; Götz M; Eichler I; Waldherr S; Dobianer K; Spona J Eur J Pediatr; 1994 Aug; 153(8):569-73. PubMed ID: 7957403 [TBL] [Abstract][Full Text] [Related]
6. Negative sweat test in hypertrypsinaemic infants with cystic fibrosis carrying rare CFTR mutations. Padoan R; Bassotti A; Seia M; Corbetta C Eur J Pediatr; 2002 Apr; 161(4):212-5. PubMed ID: 12014388 [TBL] [Abstract][Full Text] [Related]
7. Measurement of nasal potential difference in young children with an equivocal sweat test following newborn screening for cystic fibrosis. Sermet-Gaudelus I; Girodon E; Roussel D; Deneuville E; Bui S; Huet F; Guillot M; Aboutaam R; Renouil M; Munck A; des Georges M; Iron A; Thauvin-Robinet C; Fajac I; Lenoir G; Roussey M; Edelman A Thorax; 2010 Jun; 65(6):539-44. PubMed ID: 20522854 [TBL] [Abstract][Full Text] [Related]
8. Outcomes of Cystic Fibrosis Screening-Positive Infants With Inconclusive Diagnosis at School Age. Gonska T; Keenan K; Au J; Dupuis A; Chilvers MA; Burgess C; Bjornson C; Fairservice L; Brusky J; Kherani T; Jober A; Kosteniuk L; Price A; Itterman J; Morgan L; Mateos-Corral D; Hughes D; Donnelly C; Smith MJ; Iqbal S; Arpin J; Reisman J; Hammel J; van Wylick R; Derynck M; Henderson N; Solomon M; Ratjen F Pediatrics; 2021 Dec; 148(6):. PubMed ID: 34814176 [TBL] [Abstract][Full Text] [Related]
9. Correlation between genotype and phenotype in patients with cystic fibrosis. Cystic Fibrosis Genotype-Phenotype Consortium N Engl J Med; 1993 Oct; 329(18):1308-13. PubMed ID: 8166795 [TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes of children with intermediate sweat chloride values in infancy. Groves T; Robinson P; Wiley V; Fitzgerald DA J Pediatr; 2015 Jun; 166(6):1469-74.e1-3. PubMed ID: 25812778 [TBL] [Abstract][Full Text] [Related]
11. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. Massie RJ; Poplawski N; Wilcken B; Goldblatt J; Byrnes C; Robertson C Eur Respir J; 2001 Jun; 17(6):1195-200. PubMed ID: 11491164 [TBL] [Abstract][Full Text] [Related]
13. Normal sweat chloride values do not exclude the diagnosis of cystic fibrosis. Stewart B; Zabner J; Shuber AP; Welsh MJ; McCray PB Am J Respir Crit Care Med; 1995 Mar; 151(3 Pt 1):899-903. PubMed ID: 7533604 [TBL] [Abstract][Full Text] [Related]
14. Genetic counseling and neonatal screening for cystic fibrosis: an assessment of the communication process. Ciske DJ; Haavisto A; Laxova A; Rock LZ; Farrell PM Pediatrics; 2001 Apr; 107(4):699-705. PubMed ID: 11335747 [TBL] [Abstract][Full Text] [Related]
15. Sweat testing following newborn screening for cystic fibrosis. Massie J; Gaskin K; Van Asperen P; Wilcken B Pediatr Pulmonol; 2000 Jun; 29(6):452-6. PubMed ID: 10821727 [TBL] [Abstract][Full Text] [Related]
16. Refining the continuum of CFTR-associated disorders in the era of newborn screening. Levy H; Nugent M; Schneck K; Stachiw-Hietpas D; Laxova A; Lakser O; Rock M; Dahmer MK; Biller J; Nasr SZ; Baker M; McColley SA; Simpson P; Farrell PM Clin Genet; 2016 May; 89(5):539-49. PubMed ID: 26671754 [TBL] [Abstract][Full Text] [Related]
17. The relation between genotype and phenotype in cystic fibrosis--analysis of the most common mutation (delta F508). Kerem E; Corey M; Kerem BS; Rommens J; Markiewicz D; Levison H; Tsui LC; Durie P N Engl J Med; 1990 Nov; 323(22):1517-22. PubMed ID: 2233932 [TBL] [Abstract][Full Text] [Related]
18. Cystic fibrosis patients bearing both the common missense mutation Gly----Asp at codon 551 and the delta F508 mutation are clinically indistinguishable from delta F508 homozygotes, except for decreased risk of meconium ileus. Hamosh A; King TM; Rosenstein BJ; Corey M; Levison H; Durie P; Tsui LC; McIntosh I; Keston M; Brock DJ Am J Hum Genet; 1992 Aug; 51(2):245-50. PubMed ID: 1379413 [TBL] [Abstract][Full Text] [Related]